Welcome to our dedicated page for Resmed SEC filings (Ticker: RMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ResMed Inc. (RMD) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures as filed with the U.S. Securities and Exchange Commission. ResMed’s common stock is registered under Section 12(b) of the Exchange Act and trades on the New York Stock Exchange under the symbol RMD, and its filings offer detailed insight into governance, compensation, capital returns, and financial performance.
Among the key documents available are Form 8-K current reports, where ResMed discloses material events. Recent 8-K filings describe quarterly and annual results of operations, dividend declarations, and changes in the composition of the board of directors. They also cover amendments to equity-based incentive plans and the employee stock purchase plan, including increases in reserved shares and changes to plan terms approved by stockholders at the annual meeting.
Investors can also review the company’s Definitive Proxy Statement on Schedule 14A, which discusses board structure, director elections, executive compensation, and long-term strategic priorities. The proxy materials outline ResMed’s mission around sleep and breathing health, its 2030 goals, and its approach to aligning incentive programs with performance and shareholder interests.
On Stock Titan, these filings are complemented by AI-powered summaries that help explain complex sections, such as compensation plans, dividend announcements, and voting results from the annual meeting. Users can quickly see what the board has approved, how stockholders voted on proposals, and how ResMed’s capital management policies, including recurring cash dividends, are documented in its official records.
Because Form 8-K reports and proxy statements are updated over time, the filings page offers a chronological view of ResMed’s regulatory history, from financial disclosures to governance changes. This makes it a useful resource for investors who want to understand how the company reports its performance, manages equity plans, and communicates significant events through the SEC’s EDGAR system.
Form 144 filing: An affiliate, Brett Sandercock, filed notice to sell 3,000 shares of the issuer’s Common stock through Fidelity Brokerage Services on the NYSE, reflecting an aggregate market value of $742,620 and an approximate sale date of 11/03/2025.
The shares derive from two sources: 2,000 shares tied to an option granted on 11/14/2018 (cash payment dated 11/03/2025) and 1,000 shares from restricted stock vesting on 11/11/2022 (compensation). Shares outstanding were 145,966,294.
Recent activity shows prior sales by the same filer of 3,000 shares on 09/02/2025 for $812,310 and 3,000 shares on 10/01/2025 for $823,080. This notice outlines a proposed disposition method and quantity; actual sales depend on market conditions and execution.
ResMed Inc. (RMD) reported stronger Q1 FY26 results. Net revenue was $1,335,582 thousand, up 9% year over year. Gross margin improved to 61.5% from 58.6%, reflecting manufacturing and component cost efficiencies. Net income was $348,536 thousand, with diluted EPS of $2.37 versus $2.11 a year ago.
Sleep and Breathing Health revenue reached $1,169,446 thousand (up 10%), driven by higher device and mask unit sales across the U.S., Canada and Latin America and in combined Europe, Asia and other markets. Residential Care Software delivered $166,136 thousand (up 6%), led by MEDIFOX DAN, partly offset by softer Senior Living and Long‑Term Care.
Operating cash flow was $457,321 thousand. Cash and cash equivalents were $1,383,848 thousand. The company repurchased $150,010 thousand of shares and declared a $0.60 per share dividend. Total debt was $668,560 thousand, with long-term debt down and short-term borrowings up. Restructuring expenses of $15,810 thousand were recorded for workforce planning. The Federal Circuit affirmed PTAB decisions invalidating NYU’s asserted patent claims, while certain Cleveland Medical PTAB reviews proceed with decisions expected by July 2026.
ResMed Inc. (RMD) declared a quarterly cash dividend of US $0.60 per share. The dividend has a record date of November 13, 2025 and is payable on December 18, 2025. The ex-dividend date is November 12, 2025 for both NYSE common stockholders and ASX CDI holders. Payments will be made in U.S. dollars to NYSE holders, while ASX CDI holders will receive an equivalent amount in Australian dollars based on the exchange rate on the record date, reflecting the 10:1 CDI-to-NYSE share ratio.
ResMed also noted an ASX waiver allowing it to defer processing share-to-CDI conversions from November 12–13, 2025. Additionally, the company furnished a press release describing results for the quarter ended September 30, 2025.
The Vanguard Group filed an amended Schedule 13G reporting a passive stake in ResMed Inc. (RMD). As of 09/30/2025, Vanguard reported 20,007,417.40 shares beneficially owned, representing 13.66% of the class. The filing notes the holdings are in the form of depository receipts.
Vanguard reported 0 shares with sole voting power and 1,834,309.40 with shared voting power. It reported 17,643,708.00 shares with sole dispositive power and 2,363,709.40 with shared dispositive power. Vanguard certified the securities were acquired and are held in the ordinary course and not for the purpose of changing or influencing control. Its clients have rights to dividends or sale proceeds, and no single other person’s interest exceeds 5%.
Michael J. Farrell, Chief Executive Officer of ResMed (RMD), reported option exercises and stock sales executed under a Rule 10b5-1 plan adopted 10/31/2024. On 10/07/2025 he exercised 8,009 options at an exercise price of $101.64 and immediately sold 8,009 shares in multiple trades at weighted average proceeds of $282.8483 per share (runs reported between $280.95 and $283.90). Following these transactions, his beneficial ownership decreased from 475,801 shares to 467,792, with 2,090 shares held indirectly by the Lisette and Michael Farrell Family Trust. The options exercised vest on a schedule that began 11/11/2019 and expire 11/14/2025.
Form 144 notice for ResMed Inc. (RMD) reports a proposed sale of 8,009 common shares through Fidelity Brokerage Services LLC on 10/07/2025 with an aggregate market value of $2,265,331.98. The filing identifies the securities as acquired under an option granted on 11/14/2018 and lists cash as the payment method.
The notice also discloses three prior sales by the same seller, each of 8,009 shares on 07/07/2025, 08/07/2025, and 09/08/2025 with gross proceeds shown for each transaction. The filer certifies they are not aware of undisclosed material adverse information and includes the standard signature/attestation language.
ResMed Inc. filed a Form 144 disclosing a proposed sale of 4,876 common shares on the NYSE with an aggregate market value of $1,381,956.16, and 146,414,839 shares outstanding listed. The filing shows the securities were acquired on 10/07/2025 under an option granted 11/16/2022, and the proposed sale date is 10/07/2025. The broker named is Fidelity Brokerage Services LLC in Smithfield, RI. The filer certifies there is no undisclosed material adverse information and reports no securities sold in the past 3 months.
ResMed Inc. Chief Financial Officer Brett Sandercock reported insider transactions on 10/01/2025. Under a Rule 10b5-1 plan adopted 2/19/2025, he acquired 2,000 common shares by exercise of options at a strike of $101.64 and sold 3,000 shares at an average price of $274.36, leaving him with 86,745 shares beneficially owned after the transactions. The exercised options were originally exercisable beginning 11/11/2019 and expire 11/14/2025; the options vest 1/3 per year. The Form 4 was signed by an attorney-in-fact on 10/02/2025.
ResMed insider Michael J. Rider, who serves as Global General Counsel and Secretary, reported a sale of 100 shares of ResMed common stock at a price of $274.36 per share on 10/01/2025. The sale was executed under a Rule 10b5-1 plan adopted on 02/28/2025. Following the reported transaction, Mr. Rider beneficially owns 11,327 shares, held directly. The Form 4 is signed and dated 10/02/2025.
ResMed reports continued product and digital expansion in fiscal 2025 while navigating operational headwinds. The company launched new patient interfaces (AirTouch N30i, AirFit F40), expanded its AirSense 11 and AirCurve 11 platforms globally, and introduced Dawn, a generative-AI powered sleep-health assistant. Over the last 12 months ResMed increased cloud-connectable devices from 26 million to over 30 million, added 5 million patients to AirView 33 million), grew myAir users from 8.3 million to >10.3 million, and added ~15 million residential-care patient accounts 165 million).
Management reports double-digit revenue and EPS growth with expanding margins, disciplined capital deployment including share buybacks and dividend growth, and continued R&D investment (6–7% of revenue). Governance changes include board refreshment with new directors from BD and AbbVie, the planned retirement of Richard Sulpizio, an enhanced Compliance, Privacy and Quality committee, and a strengthened clawback policy. The company discloses a CEO-to-median-employee pay ratio of about 187:1.